[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:adenovirus-infection":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":93,"states":94},"Adenovirus Infection",13,12,[8,16,23,30,37,43,49,55,61,67,73,79,86],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04722029","Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory Adenovirus Infections",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:17:47.813245Z","2026-05-05T02:43:29.508195Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT03425526","Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease",[20],"Phase 1","2026-08-26T02:16:52.995882Z","2026-05-05T02:43:28.987843Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT04706923","A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection",[27],"Phase 2","2026-08-03T03:23:28.660374Z","2026-05-05T02:43:27.843415Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":35,"content_modified":36},"NCT07387367","A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT",[34],"Phase 3","2026-08-26T02:18:51.009190Z","2026-05-05T02:43:27.731458Z",{"nct_id":38,"title":39,"phases":40,"status":13,"updated_at":41,"content_modified":42},"NCT05183490","R-MVST Cells for Treatment of Viral Infections",[20],"2026-08-26T02:17:14.343713Z","2026-05-05T02:43:29.726676Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT02532452","Third Party Viral Specific T-cells (VSTs)",[27],"2026-08-26T02:19:13.549512Z","2026-05-05T02:43:28.672557Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT05101213","Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients",[20],"2026-08-03T03:52:12.406209Z","2026-05-05T02:43:28.347086Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT06926894","R-MVST Cells for Treatment of Viral Infections in Children and Young Adults",[20],"2026-08-26T02:17:53.433613Z","2026-05-05T02:43:27.623199Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT04013802","TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.",[20],"2026-08-26T02:16:09.452956Z","2026-05-05T02:43:27.168885Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06909110","Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity",[12],"2026-08-26T02:16:15.345907Z","2026-05-05T02:43:27.099634Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT04956445","Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development",[],"2026-08-26T02:16:21.385056Z","2026-05-29T15:36:40.167910Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":84,"content_modified":85},"NCT03378102","Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation",[83],"Early Phase 1","2026-08-26T02:19:11.399072Z","2026-05-05T02:43:29.078939Z",{"nct_id":87,"title":88,"phases":89,"status":90,"updated_at":91,"content_modified":92},"NCT06027879","Anti-viral T-cell Therapy by Gamma Capture",[12],"ENROLLING_BY_INVITATION","2026-08-26T02:17:35.666428Z","2026-06-16T05:54:08.096276Z",[],[95,99,102,106,109],{"state":96,"count":97,"slug":98},"Ohio",5,"ohio",{"state":100,"count":97,"slug":101},"Texas","texas",{"state":103,"count":104,"slug":105},"California",3,"california",{"state":107,"count":104,"slug":108},"New York","new-york",{"state":110,"count":104,"slug":111},"Pennsylvania","pennsylvania"]